C4 Therapeutics Inc (CCCC NASDAQ) stock market data APIs
$3.57
0.01(0.3%)
as of May 15, 2026
Try our APIs with
free plan!
C4 Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
3.57
Open
3.5755
High
3.6905
Low
3.261
52 wk Range
1.21-3.95
Market Cap
394 M
Shares Outstanding
111 M
Revenue
35 947 K
EPS
-0.1993
Beta
2.784
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with C4 Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get C4 Therapeutics Inc data using free add-ons & libraries
Get C4 Therapeutics Inc Fundamental Data
C4 Therapeutics Inc Fundamental data includes:
- Net Revenue: 35 947 K
- EBITDA: -102 530 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-13
- EPS/Forecast: -0.3035
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
C4 Therapeutics Inc News
New
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 1% on Wednesday. The Dow traded down 0.24% to 49,638.96 while the NASDAQ gained 1.18% to 26,395.66. The S&P 500...
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Wednesday. Shares of Vishay Intertechnology Inc(NYSE:VSH) rose sharply after the company reported better-than-expecte...
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combin...
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics
Company Logo The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mut...
Get C4 Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
